XtalPi signs Pierre Fabre AI drug deal

techbuzzchina.substack.com8 min read

The author examines how China's lower costs and faster research cycles provide a competitive advantage in AI drug discovery. While Western companies focus heavily on frontier AI models, Chinese firms benefit from an extensive pharmaceutical research ecosystem, lower labor costs, and faster clinical trial enrollment. The author argues that these efficiencies could prove as consequential as Western computing advantages as companies attempt to navigate high clinical attrition rates. Open article →